Stay updated on Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    No significant additions or deletions were detected; the Study Details page content appears unchanged, including eligibility criteria and locations.
    Difference
    0.4%
    Check dated 2025-11-03T21:00:23.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    33 days ago
    Change Detected
    Summary
    Update includes a prominent operating-status notice and a version upgrade from v3.1.0 to v3.2.0. The core effect is informing users about possible delays and the current open status of the NIH Clinical Center.
    Difference
    3%
    Check dated 2025-10-06T05:23:20.000Z thumbnail image
  4. Check
    40 days ago
    Change Detected
    Summary
    - Added a new version tag (v3.1.0). - Removed a specific resource (Ovarian cancer) and an older revision tag (v3.0.2).
    Difference
    0.3%
    Check dated 2025-09-29T03:02:22.000Z thumbnail image
  5. Check
    54 days ago
    Change Detected
    Summary
    Updated revision from v3.0.1 to v3.0.2. Removed the 'Back to Top' element; no changes to core content, pricing, stock, or time slots.
    Difference
    0.2%
    Check dated 2025-09-14T18:59:25.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.
    Difference
    0.2%
    Check dated 2025-09-07T14:33:06.000Z thumbnail image
  7. Check
    69 days ago
    Change Detected
    Summary
    The web page has undergone significant changes, including the addition of a facility name and location, as well as the introduction of new cancer treatment information related to ovarian cancer and specific drugs like pembrolizumab and liposomal doxorubicin. However, many related topics and previous content have been removed.
    Difference
    2%
    Check dated 2025-08-31T11:43:09.000Z thumbnail image

Stay in the know with updates to Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial page.